Nation’s First Immuno-Oncology CRO Launched by Moffitt Cancer Center in Florida

The nation’s first Immuno-oncology-focused Contract research organizations (CRO) was launched in Florida as Moffitt Cancer Center announced today that they launched a first-of-its-kind CRO focused on accelerating immunotherapy research. A new subsidiary, it represents a one-stop-shop for industry sponsors (e.g. biopharma companies) to accelerate their immune-oncology and cell therapy research through collaborative clinical trial support and administration.

Immunotherapy is Hot Topic

Immunotherapy, an emerging field in oncology, involves cell therapies such as chimeric antigen receptor T cell (CAR T) therapy. In 2017, the American Society of Clinical Oncology named CAR T-cell therapy the advance of the year. 80% of lymphoma and leukemia patients who have received CAR T therapy have benefitted from the therapy, and more than half remain in remission. Moffitt was involved in the clinical trials that led to the approval of CAR T therapy and continues to be a leader in cell therapy clinical development.

Well Positioned

Moffitt Cancer Center has enrolled more than 3,000 patients in immune-oncology trials over the past half-decade. Thomas Sellers, Ph.D., MPH, center director and execu...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee